<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01847118</url>
  </required_header>
  <id_info>
    <org_study_id>SIM-63-001</org_study_id>
    <nct_id>NCT01847118</nct_id>
  </id_info>
  <brief_title>A Phase Ia, Dose Escalation Study of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection in Patients With Advanced or Metastatic Solid Tumors</brief_title>
  <official_title>A Phase Ia, Dose Escalation Study of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection in Patients With Advanced or Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Simcere Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu Simcere Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to assess the safety, tolerability and pharmacokinetics of single dose and&#xD;
      multiple doses of humanized anti-VEGF monoclonal antibody (Sevacizumab) in patients with&#xD;
      advanced or metastatic solid tumors. The secondary objective is to explore the preliminary&#xD;
      anti-tumor effects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">November 2015</completion_date>
  <primary_completion_date type="Anticipated">November 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)</measure>
    <time_frame>up to 28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>d1, d2, d5, d8, d11, d15, d18, d22, d25,d29, d43, d57</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax</measure>
    <time_frame>d1, d2, d5, d8, d11, d15, d18, d22, d25,d29, d43, d57</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC</measure>
    <time_frame>d1, d2, d5, d8, d11, d15, d18, d22, d25,d29, d43, d57</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>d1, d2, d5, d8, d11, d15, d18, d22, d25,d29, d43, d57</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>d29, d86</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>d29, d86</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">31</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <condition>Metastatic Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Sevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2mg/kg、5mg/kg、7.5mg/kg、10mg/kg、12.5mg/kg、or 15mg/kg. d1, d29, d43, d57</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevacizumab</intervention_name>
    <arm_group_label>Sevacizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed advanced or metastatic malignant solid&#xD;
             tumors;&#xD;
&#xD;
          -  Patients failed the standard anti-tumor therapy or don't have standard regimen;&#xD;
&#xD;
          -  At least one measurable lesion;&#xD;
&#xD;
          -  At least 4 weeks from the last chemotherapy, 6 weeks from mitomycin, and nitrosourea&#xD;
             treatment. If patients received anti-tumor biological products, at least four t1/2 of&#xD;
             washout period is needed;&#xD;
&#xD;
          -  Toxicity from previous treatment has to restore to ≤ grade 1 (NCI CTC4.0);&#xD;
&#xD;
          -  ECOG performance status 0-1;&#xD;
&#xD;
          -  Life expectancy ≥ 3 months;&#xD;
&#xD;
          -  Adequate hematologic function: ANC ≥ 1.5 × 10^9 /L, HB ≥ 90 g /L (blood transfusion&#xD;
             allowed), PLT ≥ 100 × 10^9 /L;&#xD;
&#xD;
          -  Adequate hepatic function: ALT ≤ 2.5 × ULN, AST ≤ 2.5 × ULN, TBIL ≤ 1.5 × ULN&#xD;
             (patients with liver metastases ALT ≤ 5 × ULN, AST ≤ 5 × ULN, TBIL ≤ 3 × ULN);&#xD;
&#xD;
          -  Adequate renal function: creatinine ≤ 1 × ULN;&#xD;
&#xD;
          -  Coagulation function: INR ≤ 1.5 × ULN, APTT ≤ 1.5 × ULN;&#xD;
&#xD;
          -  Patients of childbearing potential (male and female) must agree to use reliable&#xD;
             methods of contraception until at least 12 weeks after the last dose.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  HCV, TP or HIV antibody positive;&#xD;
&#xD;
          -  Previously received anti-VEGF protein drugs, such as bevacizumab;&#xD;
&#xD;
          -  Histologically proven squamous cell lung cancer or squamous cell carcinoma of the head&#xD;
             and neck;&#xD;
&#xD;
          -  Active hepatitis B infection;&#xD;
&#xD;
          -  Evidence of serious infection;&#xD;
&#xD;
          -  Symptomatic brain metastases;&#xD;
&#xD;
          -  Patients with proteinuria at screening (urine protein ≥ 1+);&#xD;
&#xD;
          -  History of abdominal fistula, gastrointestinal perforation, abdominal abscess within 6&#xD;
             months prior to enrollment;&#xD;
&#xD;
          -  Serious non-healing wounds, ulcers or fractures;&#xD;
&#xD;
          -  Major surgery (excluding biopsy) or significant trauma within 4 weeks prior to&#xD;
             enrollment;&#xD;
&#xD;
          -  Active bleeding within 3 months prior to enrollment;&#xD;
&#xD;
          -  Bleeding diathesis or coagulation disorder;&#xD;
&#xD;
          -  History of arterial or venous thrombosis;&#xD;
&#xD;
          -  History of myocardial infarction or stroke within 6 months prior to enrollment;&#xD;
&#xD;
          -  Unstable angina, congestive heart failure, New York Heart Association (NYHA) class II&#xD;
             heart failure, uncontrollable arrhythmia, uncontrolled hypertension (systolic blood&#xD;
             pressure&gt; 150 mmHg and/or diastolic blood pressure&gt; 100 mmHg);&#xD;
&#xD;
          -  Pregnant and lactating women;&#xD;
&#xD;
          -  Known allergies to any excipient in the study drug;&#xD;
&#xD;
          -  Patients with alcohol or drug dependence;&#xD;
&#xD;
          -  Participation in other clinical trials within 4 weeks before enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jin Li, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin Li, MD, PhD</last_name>
      <phone>86-021-61733905</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <study_first_submitted>April 26, 2013</study_first_submitted>
  <study_first_submitted_qc>May 3, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2013</study_first_posted>
  <last_update_submitted>March 22, 2015</last_update_submitted>
  <last_update_submitted_qc>March 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

